改良预处理方案挽救性异基因造血干细胞移植治疗难治性T细胞幼淋巴细胞白血病一例报告并文献复习  

Salvage allogeneic hematopoietic stem cell transplantation of modified preconditioning regimen for refractory T-cell prolymphocytic leukemia:A case report and literature review

作　　者：薛松[1] 刘夫红 张永平 刘圆圆 王静波[1] Xue Song;Liu Fuhong;Zhang Yongping;Liu Yuanyuan;Wang Jingbo(Department of Hematology,Aerospace Center Hospital,Beijing 100049,China)

机构地区：[1]航天中心医院血液科,北京100049

出　　处：《北京医学》2020年第7期607-611,共5页Beijing Medical Journal

摘　　要：目的总结改良预处理方案挽救性异基因造血干细胞移植治疗难治性T细胞幼淋巴细胞白血病(T-cell prolymphoblastic leukemia,T-PLL)的疗效。方法选择2017年2月航天中心医院收治的使用改良预处理方案挽救性造血干细胞移植治疗的难治性T-PLL患者1例,观察移植效果及移植并发症发生情况,并进行文献复习。结果患者血细胞植入顺利,评估处于持续缓解状态,移植术后随访2年余,无严重急慢性移植物抗宿主病表现,生存质量良好。结论T-PLL是罕见的造血系统恶性肿瘤,常规治疗效果不佳,需考虑造血干细胞移植治疗。对于常规化疗原发耐药的T-PLL患者,异基因造血干细胞移植可作为挽救性治疗技术,预处理方案的优化可能会取得更佳的疗效。Objective To summarize the effect of salvage allogeneic hematopoietic stem cell transplantation of modified preconditioning regimen for refractory T-cell prolymphoblastic leukemia(T-PLL).Methods One case of refractory TPLL was treated with salvage allogeneic hematopoietic stem cell transplantation(allo-HSCT)of modified preconditioning regimen,and the effect of transplantation and the incidence of complication were observed.Results Allo-HSCT was successful.The patient was in a state of sustained remission.After transplantation,the patient were followed up for more than two years.No severe acute or chronic graft-versus-host disease performance occurred and the quality of life was good.Conclu⁃sions T-PLL is a rare hematopoietic malignancy and conventional treatment is not effective,thus HSCT should be considered.For T-PLL patients with primary resistance to conventional chemotherapy,allo-HSCT can be carried out as a salvage treatment technique,and the optimization of the preconditioning regimen may achieve better results.

关 键 词：T细胞幼淋巴细胞白血病 异基因 造血干细胞移植 

分 类 号：R733.7[医药卫生—肿瘤] R457.7[医药卫生—临床医学]